EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Mechanistic Insights of Thyroid Cancer Progression

Luis Javier Leandro-García iD, Iñigo Landa iD

Endocrinology · 01.08.2023 · 164 (9)

DOI: 10.1210/endocr/bqad118 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrinology, online erschienen am 28.07.2023. Verfasst von Luis Javier Leandro-García und 1 weiteren Autor:innen. Beteiligte Einrichtung: Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic, Adenocarcinoma. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, La Caixa Junior Leader fellow, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Differentiated thyroid cancers (DTCs) are primarily initiated by mutations that activate the MAPK signaling cascade, typically at BRAF or RAS oncoproteins. DTCs can evolve to more aggressive forms, specifically, poorly differentiated (PDTC) and anaplastic thyroid cancers (ATC), by acquiring additional genetic alterations which deregulate key pathways. In this review, we focused on bona fide mutations involved in thyroid cancer progression for which consistent mechanistic data exist. Here we summarized the relevant literature, spanning approximately 2 decades, highlighting genetic alterations that are unquestionably enriched in PDTC/ATC. We describe the relevant functional data obtained in multiple in vitro and in vivo thyroid cancer models employed to study genetic alterations in the following genes and functional groups: TP53, effectors of the PI3K/AKT pathway, TERT promoter, members of the SWI/SNF chromatin remodeling complex, NF2, and EIF1AX. In addition, we briefly discuss other genetic alterations that are selected in aggressive thyroid tumors but for which mechanistic data is still either limited or nonexistent. Overall, we argue for the importance conveyed by preclinical studies for the clinical translation of genomic knowledge of thyroid cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsThyroid Carcinoma, AnaplasticAdenocarcinomaHumansPhosphatidylinositol 3-KinasesMutationProto-Oncogene Proteins B-rafProlineThiocarbamates

Stichwörter der Autor:innen

anaplastic thyroid cancercancer genomicscancer progressionmouse modelspapillary thyroid cancerthyroid cancer pathogenesis

Substanzen

Phosphatidylinositol 3-KinasesProto-Oncogene Proteins B-rafprolinedithiocarbamateProlineThiocarbamates

Autor:innen und Institutionen

  • Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain.
  • Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA 02115, USA.

ORCID-Profile: Luis Javier Leandro-García, Iñigo Landa

Förderung

  • NCI NIH HHS
  • La Caixa Junior Leader fellow
  • National Cancer Institute
  • Career Transition Award

Zitieren

APA

Leandro-García, L. J., & Landa, I. (2023). Mechanistic Insights of Thyroid Cancer Progression. Endocrinology, 164(9). https://doi.org/10.1210/endocr/bqad118

Vancouver

Leandro-García LJ, Landa I. Mechanistic Insights of Thyroid Cancer Progression. Endocrinology. 2023;164(9). doi:10.1210/endocr/bqad118

BibTeX
@article{LeandroGarca2023,
  author = {Leandro-García, Luis Javier and Landa, Iñigo},
  title = {Mechanistic Insights of Thyroid Cancer Progression},
  journal = {Endocrinology},
  year = {2023},
  volume = {164},
  number = {9},
  doi = {10.1210/endocr/bqad118}
}
Kostenlos starten →